Integrin α5 promotes migration and invasion through the FAK/STAT3/AKT signaling pathway in icotinib‑resistant non‑small cell lung cancer cells

Yang� Yang(Shanghai Institute of Pharmaceutical Industry), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Xiaofang Che(First Hospital of China Medical University), Xuejun Hu(Zoucheng People's Hospital), Yizhe Wang(First Hospital of China Medical University), Cheng Yang(Nanchang University), Kezuo Hou(First Hospital of China Medical University), Chunlei Zheng(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Jie Wu(Shanghai Jiao Tong University)
Oncology Letters
May 24, 2021
10.3892/ol.2021.12817
Cited by 22

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412